LL-37 is the only known human cathelicidin — a 37-amino acid cationic host defense peptide named for the two leucines at its N-terminus. Naturally active against bacteria, viruses, and fungi, it also disrupts biofilms that protect pathogens from antibiotics. Clinical research spans Lyme disease, SIBO, wound healing, respiratory infections, and antimicrobial resistance applications.
Last updated: March 2026 · Sources: PubMed, NCBI
LL-37 is a 37-amino acid cationic host defense peptide — the only known human cathelicidin. Named for the two leucines (LL) at its N-terminus and its 37-amino acid length, it represents one of the body's most ancient antimicrobial strategies.
Key fact: LL-37 is naturally produced by neutrophils, macrophages, epithelial cells of the skin, lungs, gut, and reproductive tract, and keratinocytes. It's released at sites of infection and inflammation as a first-line innate immune defense — predating the adaptive immune system by hundreds of millions of years of evolution.
Encoded by the CAMP gene. Cleaved from the precursor protein hCAP18 (human cationic antimicrobial protein-18) by serine proteases upon activation. Amphipathic α-helical structure that inserts into lipid membranes.
Carries a net positive charge (+6) at physiological pH. This electrostatically attracts it to the negatively charged membranes of bacteria, fungi, and some enveloped viruses — while largely sparing mammalian cells.
Acts as both a direct-killing antimicrobial and an immunomodulator. Can activate or dampen inflammation depending on context. Recruits immune cells via FPRL1/FPR2 receptors and promotes wound healing signaling.
Vitamin D directly upregulates the CAMP gene. This is one of the clearest molecular mechanisms linking vitamin D status to infection resistance. Deficiency reduces LL-37 production across all cell types.
Unlike most antibiotics, LL-37 can penetrate and disrupt bacterial biofilms — the protective extracellular matrix that shields bacteria from immune attack and antibiotic treatment in chronic infections.
Not FDA approved. LL-37 analogs and delivery platforms are in early clinical development. Exogenous LL-37 is used as a research peptide. Endogenous levels can be boosted naturally via vitamin D, exercise, and diet.
Infection or tissue damage triggers LL-37 release from neutrophils & epithelial cells
Positive charge of LL-37 drawn to negative membrane of bacteria/fungi
Peptide inserts into membrane, forms pores or carpet disruption, cell dies
LL-37 disrupts exopolysaccharide matrix, exposing hidden bacteria
Chemotaxis signals bring in neutrophils, monocytes; modulates inflammatory response
LL-37 has demonstrated activity across a broad range of pathogens in peer-reviewed research. The following reflects published MIC (minimum inhibitory concentration) and efficacy data.
Evidence note: These percentages reflect relative research evidence strength and in vitro / preclinical efficacy — not clinical success rates. Most data is from cell culture (MIC studies) and animal models. Direct clinical translation requires caution. Bars show research maturity, not guaranteed clinical outcomes.
LL-37's biofilm-disrupting capability makes it particularly interesting for chronic infection scenarios where conventional antibiotics fail. Here's what the current research shows.
Borrelia burgdorferi forms biofilms that protect it from antibiotics and immune surveillance. In vitro studies show LL-37 disrupts Borrelia biofilms and has direct bactericidal activity. The Embers et al. research and others have explored cathelicidins as adjuncts to antibiotic therapy. No human clinical trials yet — this remains early-stage but mechanistically compelling.
LL-37 is naturally produced by intestinal epithelial cells and plays a key role in regulating gut microbiome composition. Low LL-37 expression in gut epithelium has been associated with increased susceptibility to SIBO and dysbiosis. Vitamin D supplementation, which upregulates CAMP/LL-37, has been explored as a supporting intervention for gut barrier function and microbiome health.
One of the most researched applications. LL-37 promotes wound healing through multiple mechanisms: direct antimicrobial protection, promotion of keratinocyte migration, angiogenesis stimulation, and modulation of inflammatory resolution. Topical LL-37 preparations have been studied for chronic non-healing wounds, diabetic foot ulcers, and burn injuries with promising preclinical results.
Airway epithelial cells are major producers of LL-37. Intranasal vitamin D supplementation and direct intranasal LL-37 have been explored for respiratory infections including influenza, COVID-related pathology, and chronic sinusitis. The vitamin D-LL-37 link is particularly relevant here: winter vitamin D deficiency may partly explain increased respiratory infection rates.
Several studies have examined LL-37 levels as a sepsis biomarker and potential therapeutic. Low plasma LL-37 levels correlate with worse sepsis outcomes. Supplementation research in animal models shows improved survival. The challenge: LL-37 is pro-inflammatory at high concentrations, requiring precise dosing in critical care contexts.
LL-37 is naturally present in saliva and gingival fluid. Research shows it disrupts pathogenic oral biofilms including S. mutans and P. gingivalis. Low salivary LL-37 levels have been associated with increased periodontal disease severity. Topical oral applications are under investigation.
Vitamin D3 (cholecalciferol) is converted to 1,25-dihydroxyvitamin D (calcitriol) which binds the vitamin D receptor (VDR) on the CAMP gene promoter, directly upregulating LL-37 transcription. This is one of the most well-characterized gene-vitamin relationships in human biology.
Practical implication: Maintaining vitamin D levels at 50-80 ng/mL (125-200 nmol/L) — the high-normal range — is associated with optimal CAMP gene expression. Most people in northern latitudes are deficient (below 30 ng/mL) for 4-6 months per year, which may significantly suppress innate LL-37 immune defense.
Research recommendation: 25-OH vitamin D blood test → supplement to achieve 60-70 ng/mL → re-test in 8-12 weeks. This is free, safe, and evidence-based for optimizing natural LL-37 production.
Antimicrobial spectrum: Zanetti M. "The role of cathelicidins in the innate host defenses of mammals." Curr Issues Mol Biol. 2005; PMID: 15760657
Biofilm disruption: de la Fuente-Núñez C, et al. "Broad-spectrum anti-biofilm peptide that targets a cellular stress response." PLoS Pathog. 2014; PMID: 25233085
Vitamin D-LL-37 axis: Liu PT, et al. "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response." Science. 2006; PMID: 16497887
Wound healing: Ramos R, et al. "Wound healing activity of the human antimicrobial peptide LL37." Peptides. 2011; PMID: 21338643
Antiviral activity: Barlow PG, et al. "The human cathelicidin, LL-37, provides broadspectrum virus neutralization." J Virol. 2014; PMID: 23678185
Dosing data for exogenous LL-37 is limited — most human research focuses on boosting endogenous levels. The following reflects community-reported protocols and available research data.
50–100 mcg/day
Most common research protocol. Subcutaneous injection once daily or split into AM/PM doses. Bacteriostatic water reconstitution. Store at 4°C after reconstitution.
Investigational
Intranasal delivery for respiratory applications. Typically 50-100 mcg per nostril. Research protocols vary. May be more relevant for respiratory infection prevention/treatment.
100-500 mcg/mL
Topical preparations for wound healing and skin infections. Applied directly to wound bed. Research shows accelerated epithelialization and reduced bacterial burden.
Critical dosing note: LL-37 is dose-sensitive. At lower concentrations it is immunomodulatory and antimicrobial. At higher concentrations it can be cytotoxic and pro-inflammatory. There is no established human clinical dosing for subcutaneous LL-37. The 50-100 mcg range is extrapolated from preclinical data, not human clinical trials. Start low if exploring this peptide.
| Property | LL-37 | Conventional Antibiotics |
|---|---|---|
| Mechanism | Membrane disruption (physical) | Enzyme inhibition, cell wall synthesis, protein synthesis |
| Resistance development | Low — membrane disruption is hard to evolve against | High — enzyme-targeted mechanisms susceptible to mutation |
| Biofilm penetration | Strong evidence for disruption | Limited — most antibiotics fail in biofilms |
| Broad spectrum | Bacteria + Viruses + Fungi | Narrow (most target bacteria only) |
| Immunomodulation | Yes — modulates inflammation, recruits immune cells | No direct immune modulation |
| Gut microbiome impact | Relatively selective (targets pathogens) | Broad disruption of commensal bacteria |
| Human clinical data | Limited — mostly preclinical | Extensive — decades of clinical trials |
| Availability | Research peptide only | Prescription (most) or OTC |
LL-37 is a naturally occurring human peptide, which provides some inherent safety context. However, exogenous administration introduces considerations not present with endogenous production.
Mast cell activation warning: LL-37 directly activates mast cells, triggering degranulation. For individuals with Mast Cell Activation Syndrome (MCAS) or histamine intolerance, exogenous LL-37 could worsen symptoms significantly. This is a known and documented effect — not a rare adverse reaction. Screen for MCAS before considering LL-37 protocols.
Autoimmune caution: Elevated LL-37 levels (endogenous overexpression) are associated with autoimmune conditions including psoriasis and lupus. LL-37 can activate plasmacytoid dendritic cells via TLR7/9 through complex formation with self-DNA, potentially driving autoimmune pathways. This is relevant context for anyone with autoimmune conditions considering LL-37.
Natural production is safe: Supporting endogenous LL-37 through vitamin D optimization is considered safe and well-studied. The concerning effects above primarily apply to pharmacologic exogenous dosing. Optimizing vitamin D levels to the 50-70 ng/mL range to maximize natural LL-37 production carries a well-established safety profile.
What the current research actually tells us — and where the gaps remain.
LL-37 is among the most fascinating peptides in human biology — a broad-spectrum innate immune weapon that evolution has refined for millions of years. The research case for its potential is compelling, particularly for biofilm-associated chronic infections. However, exogenous administration is ahead of the clinical evidence. The most evidence-based action remains optimizing endogenous production via vitamin D and lifestyle factors. For those exploring exogenous research protocols, extreme caution is warranted — particularly for those with MCAS, autoimmune conditions, or active inflammatory disease.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Products relevant to peptide research protocols. Affiliate links help support MeetPeptide.
Affiliate links help support MeetPeptide at no extra cost to you. As an Amazon Associate, we earn from qualifying purchases.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
⚕️ Medical Disclaimer: This page is for educational and informational purposes only. It is not medical advice and does not constitute a recommendation to use LL-37 or any other peptide. LL-37 is not FDA approved for any indication and is used only as a research compound. Exogenous LL-37 administration carries unknown risks in humans. All data referenced is from published peer-reviewed research, primarily preclinical (in vitro and animal studies). Human clinical data is severely limited. Always consult with a qualified healthcare provider before starting any peptide, supplement, or medication regimen. Do not self-treat any medical condition with research peptides. Individuals with autoimmune conditions, MCAS, or active infections should exercise particular caution.